CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 12, 2021—DiaSorin has signed a definitive merger agreement to acquire Luminex for a total equity value of about $1.8 billion.
Luminex, headquartered in Austin, Tex., develops, manufactures, and sells proprietary biological testing technologies and products throughout the diagnostics and life science industries. Through the acquisition, DiaSorin, based in Italy, will gain access to Luminex’s molecular diagnostics multiplexing technology and portfolio, including a menu of solutions in infectious diseases, respiratory infections, vector-borne diseases, hospital-acquired infections, gastroenterology infections, genetics, and women’s health, expanding DiaSorin’s presence in the United States. The acquisition will also provide DiaSorin access to Luminex’s applications in the life science industry while accelerating the availability of Luminex’s technology and solutions outside the U.S. through DiaSorin’s extensive commercial and geographical reach.